Psoriasis is an immune-mediated skin disorder associated with severe systemic co-morbidities. Both chronic and acute forms of the disease are characterised by abnormal interleukin (IL)-36 signalling.
INTRODUCTION
Interleukin-36, - and- (hence IL-36) are group of IL-1 family cytokines that are mainly produced by keratinocytes, monocytes and dendritic cells 1 . IL-36 signalling plays an important role in epithelial immune homeostasis and its de-regulation has been repeatedly implicated in the pathogenesis of plaque psoriasis (PsV), a common and chronic, immune-mediated skin disorder 1 .
Numerous studies have shown that IL-36 responses are elevated in PsV skin 2, 3, 4, 5 . Moreover, we have demonstrated that IL-36 stimulates chemokine production and amplifies the effects of IL-17 signalling in psoriatic lesions 3 . Finally, animal studies have established that IL-36 promotes the activation of dendritic cells and the polarization of T lymphocytes into Th17 cells 6 . Thus, the mechanisms whereby IL-36 contributes to cutaneous inflammation have been extensively investigated. Its systemic effects, however, remain poorly understood.
We and others have shown that recessive mutations of the IL-36 receptor antagonist (IL36RN) are associated with generalised pustular psoriasis (GPP), a disease variant characterized by severe extracutaneous symptoms 7, 8 . In fact, GPP patients suffer from flares of skin pustulation that are often accompanied by acute systemic upset (fever, elevation of acute phase reactants and neutrophilia) 9 .
This suggests that IL-36 signalling is likely to influence immune responses beyond skin.
Of note, extra-cutaneous co-morbidities are also well documented in PsV, as individuals suffering from severe disease are at high risk of psoriatic arthritis, metabolic syndrome and atherosclerosis 9, 10, 11 . It has therefore been proposed that PsV is a systemic disease, manifesting with skin, joint and vascular inflammation 12, 13 .
In this context, we hypothesise that abnormal IL-36 signalling has extra-cutaneous effects in both GPP and PsV, driving acute systemic flares in the former and contributing to a state of chronic systemic inflammation in the latter. To explore this model, we have integrated the transcription profiling of patient leukocytes with the characterisation of IL-36 responses in circulating immune cells. Our experiments show that IL-36 potentiates Toll-like receptor (TLR)-9 activation and enhances Type-I IFN production by plasmacytoid dendritic cells (pDCs). Thus, we have identified an IL-36/TLR-9 axis which up-regulates Type-I IFN, a cytokine that has been repeatedly implicated in the pathogenesis of systemic immunity, arthritis and atherosclerosis.
RESULTS

Expression profiling identifies a Type-I IFN signature in GPP and PsV whole-blood samples
We reasoned that GPP would represent an ideal model in which to investigate the systemic effects of IL-36, given the well-established link with IL36RN mutations 7, 8 and enhanced IL-36 activity 14 . We therefore undertook RNA-sequencing of whole-blood samples obtained from 9 affected individuals and 7 healthy controls (Supplementary Table 1 15 collectively showed a significant up-regulation in cases vs. controls (P=0.019) (Fig.1b) . Of note, the analysis of a publicly available PsV dataset (whole-blood samples obtained from 33 cases vs 44 controls) 16 identified a moderate, but statistically significant, over-expression of the same genes (P=0.001) (Fig.1b) , providing the first indication that IL-36 may have systemic effects in PsV.
To further explore the biological significance of our findings, we mapped the genes up-regulated in GPP to the co-expression modules described by Li ) between the genes that are up-regulated in GPP and those that are over-expressed in autoinflammatory syndromes caused by excessive Type-I IFN production (Fig. 1f) . Of note, no such overlap was found with the up-regulated genes detected in cryopyrin associated periodic syndrome (CAPS) 20 , a disease caused by excessive IL-1 activity, which was analysed as a negative control ( Supplementary Fig. 1a) . Thus, the presence of a Type-I IFN signature in GPP leukocytes is supported by several lines of evidence.
To further investigate the relevance of these observations we built an interferon score (IS) by measuring the aggregate expression of 5 Type-I IFN regulated genes (IFI6, IFIT3, IFITM3, OASL, PLSCR1). As expected, the score was elevated in GPP cases, compared to controls. A similar increase was observed in the publicly available PsV dataset (Fig. 1g) , indicating that abnormal Type-I IFN activity is also present in PsV leukocytes. Importantly, we found that the IS documented in GPP and PsV significantly correlated with the IL-36 signatures observed in these datasets (P<0.01) (Fig. 1h) . Thus, we have shown that psoriatic patients display abnormal Type-I IFN activity at the systemic level, which may be linked to increased IL-36 production. 
The Type-I IFN signature is readily detectable in GPP neutrophils
The presence of heterogeneous cell populations in whole-blood samples can complicate the interpretation of transcription profiling experiments. We therefore sought to validate our results through an independent analysis of a single cell type. Given that neutrophils play a critical role in systemic inflammation and can be activated by Type-I IFN signalling 21, 22, 23 , we focused our attention on these cells. We obtained fresh blood samples from 8 GPP cases and 11 controls. We then isolated highly pure (>95%) neutrophil populations (Supplementary Fig. 2a and Supplementary Table 1 
The Type-I IFN signature can be validated in extended PsV and GPP datasets
We next sought to validate the type I IFN signature through the analysis of further affected individuals.
We obtained whole-blood samples from 35 additional GPP patients and 7 healthy controls. We then measured the IS by real-time PCR of the IFI6, IFIT3, IFITM3, OASL and PLSCR1 transcripts. The analysis of the expanded dataset (including the validation cohort as well as the nine samples that had been originally RNA-sequenced), confirmed the up-regulation of IFN stimulated genes (P=0.02) (Fig. 3a) .
We next examined neutrophils obtained from 17 GPP cases (including 7 from the RNA-seq dataset and 10 newly ascertained cases) and 16 PsV patients. To maximise the likelihood of observing a systemic Type-I IFN signature, we selected the PsV cases among patients suffering from severe disease (average Psoriasis Area and Severity Index (PASI): 17.9). We, however, excluded individuals who were being treated with TNF inhibitors, in order to avoid the confounding effects of TNF-dependent type-I IFN modulation 25 . Finally, we included three control groups in the analysis: 9 individuals affected CAPS, 13
cases of acral pustular psoriasis (a localised variant of the disease which manifests without systemic involvement) and 26 healthy volunteers. Real-time PCR demonstrated that the IS was significantly increased in GPP and PsV cases compared to healthy controls (P<0.005 for both). Conversely, and in keeping with the specificity of our observations, the IS of CAPS and acral pustular psoriasis patients were within the normal range defined in unaffected individuals (Fig. 3b) .
Of note, a closer inspection of medical records showed that GPP patients with high IS were more likely to experience systemic flares than those with low IS (88% vs 33%; P=0.049). Likewise, high-IS PsV subjects more frequently suffered from psoriatic arthritis (80% vs 17%; P=0.03) (Fig. 3c) .
Thus, the Type-I IFN signature detected by RNA-sequencing can be validated in independent PsV and GPP samples, where it is associated with features of systemic involvement. The data are presented as mean +/-standard deviation; **P<0.01 (one-way ANOVA followed by Dunnett's post-test). (C) Left panel: systemic flares are more prevalent in GPP patients with high interferon scores (n=8) compared to those with low interferon scores (n=9). Right panel: psoriatic arthritis (PsA) is more prevalent in PsV patients with high interferon scores (n=6) compared to those with low interferon scores (n=11). In both groups, the cut-off between high and low scores was defined as the median +2SD of the values observed in healthy controls. *P<0.05 (Fisher's exact test).
The IL-36 receptor is expressed on the surface of plasmacytoid dendritic cells
Having observed a marked up-regulation of IFN signature genes in both GPP and PsV, we hypothesised that IL-36 has a direct effect on Type-I IFN producing cells. To investigate this possibility, we systematically examined the surface expression of the IL-36 receptor (IL36R) in innate immune cells.
We obtained peripheral blood mononuclear cells (PBMCs) and neutrophils from healthy donors and GPP patients. We then measured IL36R levels by flow-cytometry (Supplementary Figure 3) . In keeping with published findings 26 , we found that IL36R was barely detectable on the surface of healthy neutrophils (Fig. 4a) . We also showed that receptor levels were low in innate lymphoid cells (Fig. 4b) , in classical, intermediate and pro-inflammatory monocytes (Fig. 4c) , and only marginally higher in myeloid dendritic cells (mDC) (Fig 4d) . Finally, we observed robust receptor expression in pDCs (Fig.   4d ), a phenomenon that was especially noticeable among the GPP samples (Fig. 4e) . Thus, we have shown that IL36R is preferentially expressed in pDCs, the cell type that produces the largest amounts of Type-I IFN. (Fig. 5a ). This observation was validated by direct ELISA measurements of IFN- production, demonstrating that IL-36 pre-treatment enhanced the response to CpG (P<0.01) (Fig. 5b) . Finally, flow cytometry showed an increased proportion of IFN + pDCs among the cells that had been stimulated with IL-36 and CpG, compared to those that had been exposed to CpG alone (Fig. 5c) . Thus, multiple experimental readouts support the notion that IL-36 up-regulates TLR-9 dependent IFN- release. 
IL-36 up-regulates PLSCR1, a known TLR-9 transporter
We next sought to define the mechanisms whereby IL-36 enhances IFN- production downstream of TLR-9. A closer inspection of the PBMC stimulation results showed that IL-36 treatment can upregulate the expression of PLSCR1, even in the absence of CpG. This is of interest, as the gene encodes phospholipid scramblase 1, a protein which has been shown to interact with TLR-9 and regulate its trafficking to the endosomal compartment 27 .
To further explore the link between IL-36 and PLSCR1, we first validated our initial observation through the analysis of additional donors (Fig. 6a) . Next, we demonstrated that IL-36 treatment increases PLSCR1 protein levels in isolated pDCs, showing a direct effect of the cytokine on these cells (P<0.05) (Fig. 6b) . Finally, we investigated the mechanism whereby IL-36 up-regulates PLSCR1. As expected for an IFN signature gene, an analysis of the PLSCR1 promoter uncovered a STAT1 binding site. Given that IL-36 can signal through mitogen-activated protein kinases (MAPK) 1 , and that there have been reports of cross-talk between STAT1 and MAPK signalling 28 , we reasoned that the latter pathway was likely to be involved. Real-time PCR experiments confirmed this hypothesis, as the SB-203580 MAPK inhibitor abolished the effect of IL-36 on PLSCR1 expression (Fig. 6c) .
Thus, we have demonstrated that IL-36 can act directly on pDCs, where it up-regulates PLSCR1 transcript and protein levels, in a MAPK-dependent fashion. 
DISCUSSION
The hypothesis underlying this study was that IL-36 signalling de-regulation affects systemic responses in PsV. While the disease has been historically described as a dermatological condition, the importance of extra-cutaneous co-morbidities is increasingly recognised and so is their impact on patient mortality 29 . Of note, the prevalence of most co-morbid disorders increases with the severity and the duration of PsV 9, 30 . There is therefore a dose-dependent association between cutaneous and extracutaneous inflammation, which suggests a shared systemic pathogenesis. The underlying pathways, however, remain poorly understood.
Here, we demonstrated that IL-36 signalling is up-regulated in the leukocytes of PsV patients. We also showed that this abnormal activity correlates with a signature of Type-I IFN over-expression. Of note, several studies have found that Type-I IFN plays a key role in vascular inflammation, as it promotes macrophage-endothelial cell adhesion and stimulates the recruitment of leukocytes to atherosclerotic plaques 31, 32 .
In keeping with these observations, signatures of excessive Type-I IFN activity have been documented in various diseases presenting with prominent systemic involvement. One notable example is systemic lupus erythematosus (SLE), a multi-organ disorder that is associated with accelerated atherosclerosis, skin and joint inflammation 33 . Of interest, three independent studies have reported that IL-36 serum levels correlate with disease activity in SLE 34, 35, 36 , which further reinforces the link between IL-36 and Type-I IFN. Our study adds to these observations and provides mechanistic insights into the underlying inflammatory pathways.
Our computational and experimental results implicate pDCs as the most likely mediators of IL-36 activity. First, the analysis of the GPP RNA-sequencing data identified the activation of IRF7 as one of the most significant drivers of differential gene expression. Second, flow cytometry studies demonstrated that IL-36R surface expression is highest in pDCs, especially among GPP patients.
Finally, we showed that IL-36 acts directly on pDCs, where it up-regulates PLSCR1 mRNA and protein expression.
Of note, PLSCR1 siRNA knockout inhibits type I IFN production by human pDCs 27 , so it is reasonable to hypothesise that an increase in gene expression would have the opposite effect. While the PLSCR1 induction observed in our experiments was modest (IL-36 increased gene expression levels by 1.5-2.0 fold), it might be sufficient to set in motion a feed-forward loop whereby up-regulated PLSCR1 promotes the production of type I IFN, which in turn induces further PLSCR1 transcription. In fact, selfamplifying loops are a key feature of Type-I IFN signalling, as they are required for the establishment of robust antiviral responses 37 .
We cannot exclude the possibility that additional IL-36 responsive genes or cell types may also contribute to the up-regulation of Type-I IFN. We have found that IL-36 does not affect the expression of TLR9 or that of key downstream genes (IRF1, IRF3, IRF7; data not shown). We have also observed that genes driving other antiviral pathways (DDX58/RIG-I, IFIH1/MDA5, TMEM173/STING) are not systemically up-regulated in PsV or GPP. However, we cannot rule out an effect of IL-36 on as yet undiscovered regulators of innate antiviral immunity.
In conclusion, our computational and experimental studies have identified an IL-36/TLR-9 axis which up-regulates systemic Type-I IFN production in psoriasis (Fig. 6d) . In GPP patients, the effects of IL-36 signalling are amplified by inherited IL36RN mutations, a phenomenon which is likely to account for the severe nature of systemic flares. In PsV, the Th17-dependent up-regulation of IL-36 cytokines is associated with a less pronounced transcriptional signature and with signs of chronic systemic inflammation. Thus, IL-36 is an important immune regulator in psoriasis, contributing to the systemic pathogenesis of acute and chronic forms of the disease.
Of note, two IL-36 inhibitors are currently in clinical development. Promising results have been reported in GPP Phase I/II trials 38, 39 and further studies are underway in other conditions thought to be IL-36 mediated (e.g. ulcerative colitis, clinical trial id: NCT03648541). Thus, our study has characterised a novel innate immune axis that could be targeted for the treatment of systemic symptoms in psoriasis.
METHODS
Human subjects
The study was performed in accordance with the principles of healthy volunteers were used for the stimulation of PBMCs and pDCs.
RNA-sequencing
Total RNA was isolated from whole blood collected in Tempus™ Blood RNA Tube using a Tempus™ Spin RNA Isolation Kit (Thermo). Samples were subjected to globin depletion using a GLOBINclear™ Kit (Thermo). Neutrophil RNA was isolated with GeneJET RNA purification kit (Thermo).
Whole-blood RNA was sequenced on a HiSeq 3000 Illumina platform, obtaining 150bp paired-end reads. Neutrophil RNA was sequenced on a NextSeq 500 Illumina platform obtaining 75bp single-end reads. The quality of the sequence data was assessed using FastQC. Alignment against the HG38 human genome was implemented in TopHat 40 with indexes generated by Botwie2. Read counts produced by HTseq-count were used as input for the differential expression analysis, which was performed with DESeq2 41 (R package, v 16.2), using sex as a co-variate.
Genes with a fold change (FC) ≥1.5 and a false discovery rate (FDR) <0.05 were used as input for pathway and upstream regulator enrichment analyses (IPA, Qiagen). The latter assesses the overrepresentation of targets of known transcription regulators, while also building gene-target networks based on published co-expression and binding affinity data. Here, STAT1-STAT3-and IRF7-centered networks were visualised with the igraph v1.0.1 R Package.
The python library published by Li et al 17 was modified in order to identify blood transcriptional modules that are enriched among genes up-regulated in GPP. Briefly, the modules that were active in our datasets were selected using the genetable_to_activityscores function. Next, the enrichment_test function was applied to the lists of up-regulated genes, taking into account the module activity scores and fold change of the genes mapping to each module. Enrichment P values were then calculated and corrected for multiple testing using the Benjamini-Hochberg method.
The interferon score was built using the five Type-I IFN dependent genes that were most up-regulated in GPP whole-blood (PLSCR1, OALS, IFI6, IFIT3, IFITM3). As IL-36 dependent genes have not been systematically characterised in leukocytes, the IL-36 score was based on the analysis of five genes which were strongly induced by IL-36 in keratinocytes 3 and robustly expressed in whole-blood (IL1B, PI3, VNN2, TNFAIP6, SERPINB1 and PLSCR1). Both scores were derived by normalising RPKM values to a calibrator sample and then computing the median expression of the five signature genes.
Cell isolation and culture
Neutrophils were purified using the MACSxpress Whole Blood Neutrophil Isolation Kit (Miltenyi Biotec). PBMCs were isolated using Ficoll-Paque PLUS (GE Healthcare). Plasmacytoid dendritic cells were purified from PBMCs using a Plasmacytoid Dendritic Cell Isolation Kit (Miltenyi Biotec). PBMCs and pDCs were cultured at a density of 2.5x10 6 cells/ml and 2.5x10 5 cells/ml, respectively, in RPMI Glutamax (Gibco) supplemented with 10% FBS and 1% penicillin-streptomycin. Cells were stimulated with 50 ng/ml IL-36α (Bio-Techne) for 6 hours and with 1.6 ng/ml ODN-A CpG (Invivogen) for a further 6 hours. For IFN-α and PLSCR1 flow cytometry analysis, Brefeldin A (BioLegend) was added to the stimulated cells at a 1: 1,000 dilution after 9 hours. Response to stimulation was measured by realtime PCR, ELISA or flow-cytometry.
Real-time PCR and ELISA
RNA samples were isolated with the GeneJET RNA purification kit (Thermo). Following reverse transcription with the nanoScript2 kit (Primerdesign), gene expression was assessed by real-time PCR using PrecisionPLUS Master Mix with SYBR and ROX (Primerdesign) in conjunction with the primers listed in Supplementary Table 2 . The IFN score was derived by computing the median RQ of the five signature genes, (PLSCR1, OALS, IFI6, IFIT3, IFITM3) according to the method described by Rice et al 42 .
The production of IFN-α was measured using the Human IFN-alpha ELISA kit (Bio-Techne). For whole blood and PBMC samples, transcript levels were normalised to B2M expression, while RPL13A was used for neutrophils.
Flow cytometry
The purity of neutrophil isolated for RNA-sequencing was measured by staining cells with anti-CD45, Table 3 .
Statistics
The tests used in each experiment are reported in the legend of the relevant figure. Briefly, differences between the cytokine scores of patient and control groups were assessed using a two-tailed t-test or 
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